Ligand engagement of receptors at the cell surface induces the assembly of intracellular protein complexes that transduce signals to the cytoplasm and nucleus to activate many cellular responses. A key class of signaling molecules that mediate receptor-induced rearrangements of the actin cytoskeleton, activation of kinase cascades, and changes in gene transcription is the Rho family of GTPases (46) . Although much recent work has focused on the pathways downstream of Rho GTPases which lead to cytoskeletal changes, little is known about how receptor activation at the cell surface leads to the activation of Rho GTPases.
Vav proteins are Rho family guanine nucleotide exchange factors that are ideally suited to couple receptors to Rho GTPases because they contain multiple protein domains that can bind to receptors or receptor-associated signaling proteins (3, 35) . In addition, the best-characterized Vav protein, Vav1, is activated by two common signals generated by multiple classes of plasma membrane receptors: tyrosine phosphorylation and the phosphatidylinositol (PI) 3Ј-kinase product, PI-3,4,5-P 3 (3, 16) . Stimulation of diverse cell surface receptors including immune response receptors, integrins, and growth factor receptors leads to tyrosine phosphorylation of Vav1 (3, 6, 14, 31, 55) . Thus, Vav proteins may function to transduce signals from diverse receptors to Rho GTPases.
Vav1 was first identified by the isolation of a truncated, constitutively active form of this protein (lacking 67 amino acids at its amino terminus) that induced oncogenic transformation of NIH 3T3 cells (23) . However, the endogenous Vav1 protein is expressed exclusively in hematopoietic cells (2, 22) . Vav1 plays an important role in lymphocyte development and antigen receptor-mediated signal transduction in mice. T cells lacking Vav1 are impaired in antigen-induced cell proliferation, activation of NFAT and NFB, interleukin-2 (IL-2) production, and clustering of actin with the T-cell receptor (TCR) into patches and caps (7, 12, 13, 20, 41, 54) . Though Vav1 has also been implicated in actin cytoskeletal rearrangements induced by integrins (31), it has not been established whether Vav1 is essential for regulation of these pathways in hematopoietic cells or whether other Vav family members regulate receptor-induced cytoskeletal changes in nonhematopoietic cells.
Recently an additional Vav family member, Vav2, has been identified which is ubiquitously expressed in embryos and adult tissues (18, 37) . In this report, we describe a third Vav family member, Vav3, isolated from a mouse cDNA library. During the course of this study, the human homologue of vav3 was also reported (32) . vav3 mRNA is detected in a wide spectrum of tissues and cell lines (32) ; W. Swat, K. Fujikawa, and F. W. Alt, unpublished data). Like Vav1, Vav2 also becomes oncogenic upon deletion of its amino terminus; however, in one report the morphology of vav2-transformed cells was distinct from that of vav1-transformed cells, suggesting that there may be differences in downstream effectors of these two family mem-bers (1, 37) . In contrast, the expression of truncated versions of Vav3 does not cause oncogenic transformation but does induce the formation of actin-based structures such as lamellipodia and stress fibers (32) . As with Vav1, tyrosine phosphorylation of Vav2 or Vav3 enhances its guanine nucleotide exchange factor activity in vitro (32, 37) .
Although the plasma membrane receptors that couple with Vav1 have been well characterized, relatively little is known about the events leading to activation of Vav2 or Vav3 (which are expressed in both nonhematopoietic cells and hematopoietic cells). In addition, it is unknown whether Vav1, Vav2, and Vav3 can couple with the same cell surface receptors or whether any of these family members possess unique functional activities. Because most cells are likely to express more than one Vav family member, it is possible that each Vav protein may specifically couple with different receptor classes, or that Vav proteins are activated by the same classes of receptors but induce different cellular responses due to specific interactions with downstream effectors.
In this report, we directly compare the abilities of Vav1, Vav2, and Vav3 to couple with cell surface receptor signaling pathways. We demonstrate that transiently expressed Vav1, Vav2, and Vav3, as well as endogenous Vav2, are inducibly phosphorylated on tyrosine in response to platelet-derived growth factor (PDGF), epidermal growth factor (EGF), integrin, T-cell, and B-cell receptor activation. Interestingly, however, our studies revealed unique aspects of the way Vav proteins couple with each receptor pathway, indicating that the activation of Vav proteins is dependent on different signaling proteins in distinct cell types. In addition, we found differences in the activation of downstream signaling pathways by Vav1, Vav2, and Vav3 that provide a potential explanation for the specific defects in vav1 Ϫ/Ϫ T cells and further evidence for isoform-specific functions of Vav1, Vav2, and Vav3.
MATERIALS AND METHODS
Cloning of murine vav3 cDNA. To obtain a full-length murine vav3 cDNA, we used a nested reverse transcription (RT)-PCR strategy with primers based on a vav-related human cDNA sequence fragment obtained from S. Orkin (The Children's Hospital, Boston, Mass.). A 438-bp fragment (probe K) corresponding to nucleotides 1140 to 1578 of murine vav3 cDNA was amplified and used to screen a murine brain cDNA library (ZAP2; Stratagene); this yielded several vav3 cDNA clones extending toward the 5Ј end. Two of these clones contained a consensus Kozak ATG (25); one additionally contained approximately 400 bp of 5Ј untranslated region. To obtain vav3 cDNA sequences 3Ј of probe K, two murine expressed sequence tag clones (AA518328 and AA517102) were obtained from the American Type Culture Collection (ATCC); each of these was found to contain the 3Ј end of murine vav3 cDNA, including the 3Ј untranslated region and the poly(A) tail. Subsequently, the gaps between probe K and the 3Ј expressed sequence tag sequences were closed by RT-PCR using murine spleen or thymus mRNA. While this work was in progress, complete murine (AF067816) and human (AF118887) vav3 cDNA sequences were deposited in GenBank.
Antibodies. Antibodies for immunoprecipitation of hemagglutinin (HA)-tagged proteins were the monoclonal antibody 12CA5 (47) and the polyclonal HA probe (Santa Cruz). PDGF␤ receptor (PDGF␤R) was immunoprecipitated using a polyclonal antibody to the kinase insert region (PharMingen), and endogenous Vav1 was immunoprecipitated using a rabbit polyclonal antibody (Santa Cruz). The monoclonal antibodies HA-11 (Berkeley Antibody Company) and 4G10 (kindly provided by T. Roberts, Dana Farber Cancer Institute, Boston, Mass.) were used on immunoblots to detect HA-tagged proteins and phosphotyrosine, respectively. A rabbit polyclonal antibody which recognizes Vav2 was developed using a synthetic peptide corresponding to residues 653 to 665 of human Vav2 as antigen (Covance, Denver, Pa.). Stimulatory antibodies for Tand B-cell activation were mouse anti-human CD3⑀ (PharMingen) and goat anti-human or goat anti-mouse immunoglobulin G (IgG)-IgM (heavy plus light chain [HϩL]) (Jackson Immunoresearch Laboratories).
Cell lines, plasmids, and transfections. The HepG2 cell lines which stably express variants of PDGF␤R were described previously (44) . The A5 CHO cell line (27) (40) . The pEMCV-myc-Syk construct has been described elsewhere (31) . Cos7 and A5 CHO cells were transfected at 50 to 60% confluency with 4 g of total DNA on 100-mm-diameter tissue culture plates using 8 l of LT1 reagent (PanVera) per plate. NIH 3T3 cells were transfected using 10 l Lipofectamine reagent (Gibco-BRL) per plate. Cells were incubated with the DNA-lipid complexes 6 h in 4 ml of RPMI 1640; then 4 ml of complete growth medium was added, and cells were incubated for an additional 16 to 20 h. Cells were then serum starved for 20 to 24 h in 0.1% fetal bovine serum in Dulbecco modified Eagle medium (DMEM) (Cos7, A5 CHO, and HepG2 cells) or 0.1% calf serum in DMEM (NIH 3T3 cells); 10 7 Jurkat or Daudi cells were transfected by electroporation (Bio-Rad electroporator, 220 V, 960 F). The amounts of plasmid DNA used were as follows: for Cos7, A5 CHO, and NIH 3T3 cells, 0.05 to 0.5 g of pCF1-HA, Vav1-HA, Vav2-HA, and Vav3-HA plus 0.25 g of pEMCV-Syk; for Jurkat and Daudi cells, 5 to 40 g of pCF1-HA, Vav1-HA, Vav2-HA, and Vav3-HA plus 10 g of pNFATx3 or SV40B-luc.
Growth factor stimulation, adhesion assays, and antigen receptor activation. For growth factor stimulation of transfected cells, starvation medium was replaced with DMEM without phenol red plus EGF (50 ng/ml; R&D Systems) or PDGF-BB (100 ng/ml; Upstate Biotechnology Incorporated) unless otherwise noted or DMEM without phenol red plus vehicle control (2% bovine serum albumin in 10 mM acetic acid). After stimulation (2 min with EGF or 10 min with PDGF-BB unless otherwise noted), cells were washed once with ice-cold phosphate-buffered saline (PBS) and then lysed on plates using cold NP-40 lysis buffer (50 mM Tris-Cl [pH 7.6], 150 mM NaCl, 10 mM NaF, 1 mM Na 3 VO 4 , 10% glycerol, 1% NP-40, 1 mM phenylmethylsulfonyl fluoride, 2 g each of leupeptin, aprotinin, and pepstatin per ml) for 10 min at 4°C. Plates were then scraped, and the crude lysate was transferred to tubes and cleared by centrifugation at 16,000 ϫ g for 10 min at 4°C.
Adhesion assays were performed essentially as described elsewhere (31) . Briefly, serum-starved cells were harvested and held in suspension for 30 min before replating. Cells were plated on fibronectin-coated plates (10 g/ml) and allowed to adhere 15 to 20 min. Nonadherent cells were removed from matrixcoated plates, and the adherent cells were lysed in 300 l of cold NP-40 lysis buffer. Suspended cells were held in a small volume of DMEM without phenol red and then lysed in an equal volume of cold 2ϫ NP-40 lysis buffer. Lysates were clarified by centrifugation at 16,000 ϫ g for 10 min at 4°C.
Jurkat T-lymphoid and Daudi B-lymphoid cells were stimulated 16 to 24 h after transfection. Cells were washed once in PBS, resuspended at 10 8 cells/ml, and then incubated for 5 min at 37°C with or without the addition of stimulatory antibodies: mouse anti-human CD3⑀ (10 g/ml) followed by goat anti-mouse IgG-IgM (HϩL) (10 g/ml) for Jurkat T cells, or goat anti-human IgG-IgM (HϩL) (10 g/ml) for Daudi B cells. Stimulations were terminated by the addition of excess cold PBS; cells were then washed once and lysed in 100 l of cold lymphocyte lysis buffer (50 mM Tris-Cl [pH 8.0], 150 mM NaCl, 0.5% NP-40) containing protease and phosphatase inhibitor cocktails (Boehringer Mannheim). Lysates were clarified by centrifugation at 10,000 ϫ g for 10 min at 4°C.
Immunoprecipitation and immunoblotting. Protein concentrations of cleared lysates were determined using the bicinchoninic acid protein assay (Pierce). For immunoprecipitation, 250 to 500 g of protein in a total volume of 500 l of NP-40 lysis buffer was incubated with 1 g of antibody and 30 l of a 50:50 slurry of protein A-conjugated Sepharose beads (Pharmacia or Bio-Rad) with rotation for 2 to 3 h at 4°C. Immunoprecipitates were washed twice with cold NP-40 lysis buffer, resuspended in 2ϫ sodium dodecyl sulfate sample buffer, and frozen at Ϫ20°C. Samples were boiled 5 min before loading on sodium dodecyl sulfatepolyacrylamide gels for analysis. After electrophoresis, proteins were transferred to polyvinylidene difluoride membrane (Bio-Rad); the membrane was then blocked in 5% bovine serum albumin in Tris-buffered saline containing 0.1% Tween 20 and incubated with primary antibody followed by horseradish peroxidase-conjugated secondary antibody (Bio-Rad). Signals were visualized by chemiluminescence.
Luciferase assay for NFAT and NFB activation. Jurkat T cells were cotransfected by electroporation with either pNFATx3-luciferase (17) or SV40B-luc (43) reporter construct plus pCF1-HA, Vav1-HA, Vav2-HA, or Vav3-HA. Following electroporation, cells were resuspended in culture medium and incubated for 16 to 18 h at 37°C in a humidified CO 2 incubator. For stimulations, cells were diluted to 10 6 cells/ml and incubated 8 h at 37°C with or without the addition of stimulatory antibodies. Cells were washed once in PBS and lysed in 200 l of cold lymphocyte lysis buffer; then luciferase was assayed using the Promega luciferase assay system and a luminometer (AutoLumat LB953; EG&G Berthold).
RESULTS
Sequence comparisons between Vav1, Vav2, and Vav3 proteins. We cloned the murine vav3 cDNA using a RT-PCR strategy combined with standard cDNA library screening (see VOL. 20, 2000 Vav PROTEINS COUPLE TO DIVERSE RECEPTORSMaterials and Methods). Sequence comparison of the human and mouse Vav3 proteins ( Fig. 1 ) reveals 95% identity over their 847 residues. The overall domain structure of Vav3 is analogous to that of Vav1 and Vav2 ( Fig. 2A) . The carboxy-terminal SH3 (C-SH3) domains of all three Vav proteins are highly homologous and share consensus residues found in the SH3 domains of Src and other proteins. These include the key residues predicted to form the binding site for a core PXXP ligand ( Fig. 2B) (11, 53) . Thus, all three Vav proteins would be predicted to bind similar PXXP ligands through their C-SH3 domains.
In contrast, the amino-terminal SH3 (N-SH3) domains of the Vav proteins diverge from standard SH3 domains, notably in the residues predicted to contact a PXXP ligand (Fig. 2C) . The Vav N-SH3 domains lack a tyrosine residue corresponding to Y136 of the Src SH3 domain. This tyrosine is predicted to form part of a hydrophobic pocket involved in binding a proline residue in the ligand (11, 53) . The analogous residues in the three Vav proteins are strikingly divergent in character: arginine in Vav1, serine in Vav2, and alanine in Vav3. In addition, the N-SH3 domain of Vav3 contains a substitution of phenylalanine for the highly conserved tryptophan corresponding to residue 118 of Src. Although conservative, only a small number of SH3 domains contain this substitution, and no ligand has been identified for any such SH3 domain. In addition, the RT loop (residues between the A and B ␤ strands) of the N-SH3 domain of each Vav protein contains an insertion (six residues for Vav1 and Vav3; four residues for Vav2) but no acidic residue that corresponds to the highly conserved D99 of the Src SH3 domain (Fig. 2C) . The extended RT loops of the amino-terminal Vav SH3 domains contain multiple proline residues that may serve as ligands for other SH3 domains. Vav1 contains a PPPP motif that is required for binding to a Grb2 SH3 domain (51) . Though Vav2 contains a related sequence in this same position, PPAP, Vav3 lacks the final proline (PPPA in human; PAPG in mouse) and thus does not fit as a consensus SH3-binding ligand.
The SH2 domains of all three Vav proteins are highly homologous; the residues predicted to interact with a phosphotyrosine-containing ligand are identical (10, 48) (Fig. 2D) . The residues in the Vav SH2 domains predicted to interact with the ϩ1, ϩ2, and ϩ3 positions of the ligand (corresponding to residues 200, 202, 205, 214, and 215 of the Src SH2 domain [48] ) are either identical or highly conserved between the three Vav proteins, suggesting that the SH2 domain of each Vav protein may bind ligands with similar sequences.
The linker sequences bordering the SH2 and SH3 domains are not well conserved between the three Vav proteins. Strik- ingly, Vav2 contains an additional 32 residues between the SH2 and the C-SH3 domains compared to Vav1 (27 residues compared to Vav3). A vav2 cDNA has been isolated that lacks sequences encoding 29 of the residues in this linker region, suggesting that this insert may be generated by alternative splicing (18) .
Vav1, Vav2, and Vav3 are tyrosine phosphorylated in response to EGF and PDGF. Although Vav1 can be tyrosine phosphorylated following stimulation by EGF and PDGF (5, 29), Vav1 is not normally found in cells that express the receptors for these growth factors. Vav2 and Vav3, which are expressed more widely, represent potential physiological targets of these growth factors and may link growth factor receptors to Rho GTPases in nonhematopoietic cells. To address whether these Vav isoforms can be activated by EGF and PDGF, we examined the ability of these growth factors to induce tyrosine phosphorylation of transiently expressed HAtagged variants of each Vav family member and also examined the phosphorylation of the endogenous Vav2 protein. Together, these approaches allowed us to directly assess the relative extent to which each Vav protein could be phosphorylated in response to activation of each growth factor receptor and to determine whether the endogenous Vav2 protein was also able to couple with these receptors. We were unable to analyze endogenous Vav3 due to lack of a suitable antiserum.
Plasmids encoding HA-tagged variants of Vav1, Vav2, and Vav3 were transiently transfected into Cos7 cells and NIH 3T3 cells. Treatment of serum-starved transfected Cos7 cells with EGF or NIH 3T3 cells with PDGF resulted in an increase in the tyrosine phosphorylation of HA-tagged Vav1, Vav2, and Vav3 ( Fig. 3A and B) . A tyrosine-phosphorylated band of approximately 170 kDa coprecipitated with each Vav protein in the samples from EGF-stimulated cells (Fig. 3A) . This band was confirmed as the EGF receptor (EGFR) by immunoblotting duplicate samples (S. L. Moores and J. S. Brugge, unpublished data). Likewise, the PDGFR coprecipitated with each Vav protein in PDGF-stimulated cells (Fig. 3B) . Thus, each Vav protein was inducibly tyrosine phosphorylated in response to stimulation with EGF or PDGF and formed a complex with the activated receptor.
To examine the endogenous Vav2 protein, a polyclonal antibody was raised to a Vav2-specific peptide sequence. This antibody, which does not cross-react with Vav1 or Vav3 (Moores and Brugge, unpublished), was used to immunoprecipitate endogenous Vav2 from Cos7 cells following treatment with EGF for the times and doses indicated in Fig. 3C . EGF induced rapid tyrosine phosphorylation of Vav2, which reached a maximal level within the shortest interval tested (2 min). The EGF dose necessary for maximal induction was approximately 25 ng/ml, and the response was not diminished at doses up to 100 ng/ml. PDGF also induced a rapid tyrosine phosphorylation of endogenous Vav2 (see below). While this study was in progress, Pandey and coworkers described EGF-and PDGFinduced tyrosine phosphorylation of endogenous Vav2 (33) . In agreement with our data, they also reported coprecipitation of activated EGFR or PDGFR with Vav2.
Tyrosine phosphorylation of Vav2 can be mediated through multiple individual tyrosine residues in the PDGF␤R. Vav proteins and activated receptor tyrosine kinases are likely to interact via the SH2 domain of Vav and phosphorylated tyrosine residues on the receptors (5, 29) . To examine which tyrosine phosphorylation sites on the PDGF␤R were sufficient to induce phosphorylation of Vav2, we examined the ability of several previously characterized PDGF␤R mutants (44) to induce tyrosine phosphorylation of endogenous Vav2 (Fig. 3D) . The F5 mutant contains phenylalanine substitutions for tyrosine residues 740, 751, 771, 1009, and 1021 (44) . Each derivative mutant contains a single tyrosine residue (and in one case, two tyrosine residues) added back to the F5 receptor (Fig. 3D) . Adding back these tyrosine residues recreates the binding sites for PI 3Ј-kinase (Y740/751), Ras-specific GTPase-activating protein (Ras-GAP) (Y771), SHP2 (Y1009), or phospholipase C␥1 (PLC␥1) (Y1021) (24, 44) .
These PDGF␤R mutants were stably expressed in HepG2 cells, which express very little PDGF␣R and no endogenous PDGF␤R (45) . Therefore, stimulation of the transfected cell lines with PDGF leads to activation of the stably expressed exogenous PDGF␤R. In HepG2 cells stably expressing wildtype PDGF␤R, immunoprecipitated endogenous Vav2 was tyrosine phosphorylated after treatment with PDGF (Fig. 3D) . Treatment of the HepG2 cells expressing F5 or Y1009 receptor with PDGF did not cause an increase in tyrosine phosphory- lation of Vav2, even though these receptors were expressed at a high level (Fig. 3D) . However, PDGF did cause an increase in Vav2 tyrosine phosphorylation in HepG2 cells expressing the Y740/751 or Y771 receptor (Fig. 3D) . A small but reproducible PDGF-induced increase in Vav2 tyrosine phosphorylation was also detected in cells expressing the Y1021 receptor (Fig. 3D) . Therefore, tyrosine phosphorylation of Vav2 can be mediated through several distinct tyrosine residues on the PDGF␤R, suggesting that Vav proteins can bind directly to multiple sites on the receptor or can couple with proteins that bind to multiple sites on the receptor.
Tyrosine phosphorylation of Vav proteins in response to integrin activation requires Syk. Vav1 becomes tyrosine phosphorylated in response to stimulation of several integrin family receptors in hematopoietic cells (6, 14, 55) . In addition, we have reconstituted integrin-induced tyrosine phosphorylation of Vav1 in CHO cells expressing the platelet integrin receptor ␣ IIb ␤ 3 and the tyrosine kinase Syk (31). Vav1 and Syk coexpression causes a strong Rac-dependent enhancement of lamellipodium formation in CHO cells attached to fibrinogen (31) , suggesting that Vav1 is able to couple with Rac to enhance the assembly of lamellipodia in response to integrin engagement. These studies raised the possibility that other Vav isoforms may couple integrins to Rac in nonhematopoietic cells.
To examine whether Vav2 or Vav3 could be tyrosine phosphorylated in response to integrin activation in this reconstituted CHO cell system, plasmids encoding HA-tagged Vav1, Vav2, or Vav3 were transiently transfected, and cells were either held in suspension or plated on fibronectin prior to lysis and immunoprecipitation of the Vav proteins. We were unable to detect tyrosine phosphorylation of any Vav protein after attachment of cells to fibronectin, although the Vav proteins were expressed at high levels (Fig. 4A, left) . These results indicated that integrin fibronectin receptors were unable to couple with tyrosine kinases capable of phosphorylating Vav proteins in CHO cells.
Because Syk is required for Vav1 phosphorylation mediated by ␣ IIb ␤ 3 in CHO cells (31), we examined whether Syk expression could also allow Vav2 and Vav3 to couple with fibronectin receptors. Coexpression of Syk with each Vav protein individually caused an inducible increase in tyrosine phosphorylation on Vav when the cells were plated on fibronectin (Fig. 4A,  right) . A 72-kDa tyrosine-phosphorylated protein coprecipitated with each Vav protein only in cells where Syk was expressed, suggesting that Syk is able to interact with each of the three Vav proteins. These results introduced the possibility that Vav coupling with integrins may be limited to hematopoietic cells where integrins can activate the protein tyrosine kinase Syk.
To further explore this possibility, we examined whether endogenous Vav2 could be phosphorylated following engagement of fibronectin receptors in Cos7 cells where Vav2 was phosphorylated in response to growth factor stimulation (as shown in Fig. 3C ). Vav2 was immunoprecipitated from Cos7 cells held in suspension or attached to fibronectin. As in CHO cells, there was no detectable increase in tyrosine phosphorylation of Vav2 following plating of cells on fibronectin (Fig.  4B ). In the same samples, there was induction of tyrosine phosphorylation of focal adhesion kinase (FAK) (Fig. 4B) , demonstrating that integrin receptors were efficiently activated (34) . EGF treatment of a parallel culture was included as a positive control (Fig. 4B) . There was also no detectable increase in tyrosine phosphorylation of Vav2 in Cos7 cells following plating on laminin or collagen (Moores and Brugge, unpublished). These results suggest that integrin receptor activation of Vav proteins may be limited to cells expressing particular tyrosine kinases like Syk that are able to phosphorylate Vav. VOL. 20, 2000 Vav PROTEINS COUPLE TO DIVERSE RECEPTORSVav1, Vav2, and Vav3 are tyrosine phosphorylated in response to lymphocyte antigen receptor activation. Vav1 becomes phosphorylated on tyrosine in response to both B-cell receptor (BCR) and TCR activation (4, 5, 29) ; loss of Vav1 in mice causes defects in the development of lymphocytes in vivo and antigen receptor-induced responses in vitro (7, 12, 13, 20, 41, 54) . These results suggest a unique function for Vav1 in lymphocytes and raise the questions whether other isoforms of Vav can be activated by BCR and TCR and whether Vav isoforms have distinct functional activities. To address these questions, we examined whether Vav2 and Vav3 can be tyrosine phosphorylated after engagement of these receptors. We used the Jurkat and Daudi immortalized T-and B-cell lines for these studies because their responses to engagement of antigen receptors are well characterized and they can be efficiently transfected. Jurkat and Daudi cells were transiently transfected with plasmids encoding HA-tagged Vav1, Vav2, or Vav3, and tyrosine phosphorylation of individual tagged Vav proteins was examined after cell stimulation with antibodies to the antigen receptor complexes. All three Vav proteins were inducibly phosphorylated on tyrosine in both Jurkat and Daudi cells upon engagement of antigen receptors (Fig. 5A and B) . TCR engagement in Jurkat T cells reproducibly induced a slightly higher level of tyrosine phosphorylation of Vav1 than of Vav2 or Vav3 (Fig. 5B) , while the engagement of BCR in Daudi B cells induced similar levels of tyrosine phosphorylation of Vav1, Vav2, and Vav3 (Fig. 5A) .
We also examined the tyrosine phosphorylation of the endogenous Vav1 and Vav2 proteins in T lymphocytes following TCR activation. Both Vav1 and Vav2 were inducibly tyrosine phosphorylated after TCR stimulation in Jurkat T cells (Fig.  5C ). Endogenous Vav3 was also reported to be phosphorylated after TCR stimulation in Jurkat T cells (33) . Thus, all three Vav proteins can couple with antigen receptors in T and B lymphocytes.
Differential effects of Vav1, Vav2, and Vav3 on activation of NFAT-and NFB-dependent transcription in antigen receptor-stimulated T cells. Because all three Vav isoforms were tyrosine phosphorylated in response to TCR engagement, we could not explain the defects in antigen receptor-induced NFAT-and NFB-dependent transcription and IL-2 production observed in vav1 Ϫ/Ϫ mice (7, 12, 13, 20, 41, 54) by the inability of Vav2 and Vav3 to couple with the TCR complex. We hypothesized that Vav2 and Vav3 might not be able to activate Vav1 downstream effector pathways controlling cytokine gene expression in T cells. To test this hypothesis, we examined the ability of Vav1, Vav2, and Vav3 to synergize with TCR signaling to activate transcription of an NFAT-or NFBdependent luciferase reporter gene. Consistent with previously reported results (19, 49, 50) , stimulation of Jurkat T cells with anti-CD3 antibodies resulted in activation of both NFAT-and NFB-dependent transcription, which was strongly potentiated by overexpression of Vav1 in each case (Fig. 6) . In contrast, similar levels of expression of Vav2 had little or no effect on NFAT (Fig. 6A) or NFB (Fig. 6B ) activity in response to TCR stimulation. Though expression of Vav3 also failed to potentiate NFAT-dependent transcription (Fig. 6A) , it was able to activate NFB to levels similar to those observed with Vav1 (Fig. 6B) . These results suggest functional overlap between Vav1 and Vav3 in the pathway leading to NFB induction but a specific role for Vav1 in a pathway leading to NFAT activation, which could at least partially account for impaired antigen responses in Vav1-deficient lymphocytes.
DISCUSSION
In this report, we demonstrate that the Vav1, Vav2, and Vav3 proteins are each tyrosine phosphorylated in response to activation of receptor tyrosine kinases, lymphocyte antigen receptors, and integrins, suggesting that the known Vav isoforms do not display significant differences in coupling with cell surface receptors. However, our studies revealed differences in specific aspects of signal transduction involving Vav proteins in each receptor system. For example, we were unable to detect integrin-induced tyrosine phosphorylation of Vav proteins in nonhematopoietic cell lines unless the protein tyrosine kinase Syk was coexpressed. Because Syk is expressed in all hematopoietic cell types in which Vav1 is known to be activated following engagement of integrins (6, 14, 55) , these results suggest Syk may allow integrins to couple with Vav in hematopoietic cells. Thus, while the coupling of Vav proteins to receptor tyrosine kinases occurs in both hematopoietic and nonhematopoietic cells, integrin coupling with Vav proteins appears to be dependent on the activation of particular protein tyrosine kinases like Syk and therefore is limited to certain cell types where these kinases are expressed.
Src family tyrosine kinases (Lck and Fyn) (15, 30) , Syk family tyrosine kinases (Syk and Zap70) (9, 30) , and receptor tyrosine kinases (EGFR and PDGFR) (5, 29) have been implicated as mediators of Vav tyrosine phosphorylation. Although it is likely that Vav proteins form a complex with activated receptor tyrosine kinases and can be substrates for them in vitro, it is not Although our studies suggest that integrin coupling to Vav may be limited to cells expressing Syk family kinases, we cannot rule out the possibility that integrin-activated protein tyrosine kinases other than those examined in this report can phosphorylate Vav in nonhematopoietic cells. Because we were unable to detect an increase in tyrosine phosphorylation of Vav in Cos7 or CHO cells attached to fibronectin, it is likely that the protein tyrosine kinases activated by fibronectin receptors in these cells (Src family kinases [21] , Abl [28] , and Fak [34] ) are unable to couple with Vav. Similarly, B. Liu and K. Burridge could not detect integrin-induced tyrosine phosphorylation of Vav2 in 293 or NIH 3T3 cells, other nonhematopoietic cell lines (unpublished data). However, Yron et al. reported that in another CHO cell line, adhesion to fibronectin induced the tyrosine phosphorylation of Vav1 (52) . Because this CHO cell line is able to proliferate in suspension and thus is anchorage independent, it is possible that these cells express an activated kinase capable of phosphorylating Vav. Integrins may be able to activate Vav proteins independently of tyrosine phosphorylation, and so the inability to detect integrin-induced tyrosine phosphorylation of Vav in CHO, Cos7, 293, and NIH 3T3 cells may not reflect an inability of integrins to activate Vav in these cells.
Syk family tyrosine kinases may also be required for coupling of Vav proteins to other receptor types. Tyrosine phosphorylation of Vav1 in response to Fc⑀RI activation requires coexpression of Syk in Cos7 cells (42) . In T cells lacking the Syk-related tyrosine kinase ZAP-70, no TCR-induced tyrosine phosphorylation of Vav1 is detected (36) . Although the Src family kinases Lck and Fyn have been implicated in Vav phosphorylation in T cells, it is not clear whether they act directly on Vav in these cells or whether they are required for ZAP-70 or Syk activation. Therefore, the specific protein tyrosine kinases that directly phosphorylate Vav proteins in response to activation of cellular receptors are still not known but are likely to be distinct tyrosine kinases depending on the receptor type activated.
There were no significant differences in the extent of tyrosine phosphorylation of Vav1, Vav2, and Vav3 in response to any of the receptors examined, suggesting that there is redundancy at the level of receptor activation of Vav proteins. The strong homology between the SH2 domains of Vav1, Vav2, and Vav3 may explain why all three proteins respond similarly to receptor tyrosine kinase activation. Because the SH2 domain of Vav1 (5, 29) or Vav2 (33) is sufficient to mediate the interaction between these Vav isoforms and tyrosine-phosphorylated growth factor receptors, and because Vav1, Vav2, and Vav3 proteins efficiently coprecipitated with activated growth factor receptors in our study, it is likely that the SH2 domain of each Vav protein mediates direct interactions with growth factor receptors. In addition, we have found that a glutathione S-transferase fusion protein containing the carboxyl-terminal adapter domain (SH3-SH2-SH3) of Vav2 can bind to tyrosinephosphorylated PDGF␤R immobilized on a filter membrane, indicating that Vav2 can bind directly to the PDGFR (Moores and Brugge, unpublished).
Surprisingly, there are multiple individual tyrosine residues on the activated PDGF␤R that are able to mediate Vav2 tyrosine phosphorylation. The sequences near each of these residues on the PDGF␤R are consistent with the binding preferences defined for Vav1 SH2 ligands-either Met in position ϩ1 relative to the phosphorylated tyrosine or Pro in position ϩ3 (39) . Notably, the site on PDGF␤R that did not mediate Vav2 tyrosine phosphorylation (Y1009) does not contain either of these residues in the ϩ1 or ϩ3 position. Because multiple tyrosine residues on PDGF␤R are capable of mediating Vav2 tyrosine phosphorylation, it is predicted that removing a single tyrosine residues in PDGF␤R will not inhibit downstream pathways controlled by Vav. Additionally, because Vav proteins share binding sites on PDGF␤R with other proteins such as PI 3Ј-kinase, RasGAP, and PLC␥1, overexpression of a catalytically inactive form of Vav would likely VOL. 20, 2000 Vav PROTEINS COUPLE TO DIVERSE RECEPTORSinterfere with multiple signaling pathways downstream of the PDGF␤R. Although there were no significant differences in induction of tyrosine phosphorylation of the three Vav isoforms investigated in this study, there may be differences in downstream effectors of each Vav protein. Such differences could explain why Vav1-deficient mice display defects in TCR-mediated signaling despite the evidence that all three isoforms of Vav are expressed in T cells and are inducibly phosphorylated following stimulation of the TCR in Jurkat T cells (Fig. 5C and reference (32) . We have demonstrated that one difference between the three Vav proteins is in their abilities to potentiate NFAT-and NFB-dependent transcriptional activity in response to TCR stimulation. Overexpression of Vav1 dramatically potentiated antigen-induced activation of NFAT relative to overexpression of Vav2 or Vav3. This result provides at least one explanation for the specific defect in NFAT activation in vav1 Ϫ/Ϫ T cells. Enhancement of a distinct transcriptional pathway, that involving NFB, showed a different pattern of Vav isoform specificity. Overexpression of either Vav1 or Vav3, but not Vav2, was able to potentiate antigen-induced activation of NFB. In the context of our overexpression experiments in Jurkat T cells, we cannot distinguish if the potentiation of NFB-dependent transcription by Vav1 or Vav3 is due to the use of common or alternative components of the TCR signaling apparatus. The evidence that Vav1-deficient T cells display a partial loss of NFB activity (7) suggests that Vav3 is not able to fully compensate for the loss of Vav1. Taken together, these results suggest that each Vav family member displays isoform-specific differences in the activation of downstream signaling pathways.
It is not clear which Vav functional domains are necessary to activate NFAT. Surprisingly, the GDP/GTP exchange activity of Vav1 is not required for NFAT-dependent transcription (26) . Deletion of the first 67 residues of Vav1, however, abolishes its ability to synergize with TCR engagement to enhance NFAT-dependent transcription in Jurkat T cells (20, 49) , suggesting that this amino-terminal region may be required for activation of NFAT. This region of Vav1 is not likely to be sufficient for NFAT activation because overexpression of the amino-terminal region alone or a Vav1 protein lacking the carboxyl-terminal adapter domain (SH3-SH2-SH3) does not reproduce the effect of full-length Vav1 (49) . In addition, the carboxy-terminal adapter domain of Vav1 alone is not sufficient for enhanced NFAT activation because overexpression of this domain also fails to potentiate NFAT activity in Jurkat T cells (50) . Thus, there are likely to be multiple regions of Vav1 that are necessary to induce NFAT-dependent transcription.
Differences in the substrate specificity of the guanine nucleotide exchange domain of each Vav protein could provide one explanation for differential Vav protein signaling to downstream pathways. The preferences of each Vav protein for the different Rho GTPases are unclear, as conflicting results have been reported (1, 8, 15, 16, 32, 38) . In addition, the N-SH3 domains of the three Vav proteins not only diverge from the consensus SH3 domain but also differ from each other and thus may result in different interactions with downstream signaling molecules. Likewise, the differences in the polyproline sequences of each Vav protein may also specify binding to distinct SH3 domains. Differences in expression levels of each Vav protein in distinct cell types may also determine the extent to which Vav-mediated cellular events are activated following receptor engagement. There may also be differences in localization or compartmentalization between the Vav proteins that affect their functions in cells where multiple Vav proteins are expressed.
Because Vav proteins activate Rho GTPases, it is likely that these proteins directly couple receptor activation to downstream rearrangements of the actin cytoskeleton. Indeed, one defect in vav1 Ϫ/Ϫ T cells is in patching and capping of TCRs, an event dependent on actin polymerization. We have shown that Vav proteins are tyrosine phosphorylated in response to activation of diverse receptors at the cell surface. Other studies have demonstrated that Vav proteins have the ability to reorganize the actin cytoskeleton through activation of Rho family GTPases (3, 46) . Thus, Vav proteins are likely to be critical integrators of receptor signals and direct effectors of the changes in the actin cytoskeleton involved in cellular adhesion, migration, and invasion.
